Abstract
Receptors of glutamic acid are known for over 30 years for their action and for about 20 years for their structure. Presence of at least three classes of ionotropic receptors was confirmed at the beginning of 80’. Recognition of the sequence and first cloning were done at the beginning of 90’. In 1994 ligand binding site was recognized at the junction of two subunits S1-S2 in the ligand-binding domain.
Since then, many subtypes of ionotropic and metabotropic glutamate receptors were recognized, together with their localization and functions.
In the meantime numerous orthosteric ligands, both agonists and antagonists were developed especially for NMDA ion channels. Their usefulness as drugs was rather low, due to the involvement in the excitatory tract. More interest was focused on metabotropic receptors, which are GPSR’s and can be modulated both by orthosteric and allosteric modulators.
It seems like allosterism could be considered as promising future for glutamate receptors and ion channels, especially when first allosteric negative modulators of the mGluR2 went close into the clinical trial.
Keywords: iGluR, mGluR, NMDA, AMPA, KA, AMPA auxiliary proteins, allosteric mGluR PAM and NAM modulators.
Anti-Cancer Agents in Medicinal Chemistry
Title:Potential Future of New Glutamate Agonists and Antagonists Development
Volume: 18 Issue: 4
Author(s): Dariusz Matosiuk*
Affiliation:
- Department of Synthesis and Chemical Technology of Pharmaceutical Substances, Faculty of Pharmacy, Medical University, Chodzki 4A, 20-093 Lublin,Poland
Keywords: iGluR, mGluR, NMDA, AMPA, KA, AMPA auxiliary proteins, allosteric mGluR PAM and NAM modulators.
Abstract: Receptors of glutamic acid are known for over 30 years for their action and for about 20 years for their structure. Presence of at least three classes of ionotropic receptors was confirmed at the beginning of 80’. Recognition of the sequence and first cloning were done at the beginning of 90’. In 1994 ligand binding site was recognized at the junction of two subunits S1-S2 in the ligand-binding domain.
Since then, many subtypes of ionotropic and metabotropic glutamate receptors were recognized, together with their localization and functions.
In the meantime numerous orthosteric ligands, both agonists and antagonists were developed especially for NMDA ion channels. Their usefulness as drugs was rather low, due to the involvement in the excitatory tract. More interest was focused on metabotropic receptors, which are GPSR’s and can be modulated both by orthosteric and allosteric modulators.
It seems like allosterism could be considered as promising future for glutamate receptors and ion channels, especially when first allosteric negative modulators of the mGluR2 went close into the clinical trial.
Export Options
About this article
Cite this article as:
Matosiuk Dariusz *, Potential Future of New Glutamate Agonists and Antagonists Development, Anti-Cancer Agents in Medicinal Chemistry 2018; 18 (4) . https://dx.doi.org/10.2174/1871520618666180404125041
DOI https://dx.doi.org/10.2174/1871520618666180404125041 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Parathyroid Hormone Determination in Ultrasound-Guided Fine Needle Aspirates Allows the Differentiation between Thyroid and Parathyroid Lesions: Our Experience and Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Cellular Targets and Mechanisms in the Cytotoxic Action of Non-biodegradable Engineered Nanoparticles
Current Drug Metabolism From Antimicrobial to Anticancer Peptides: The Transformation of Peptides
Recent Patents on Anti-Cancer Drug Discovery Multi-Targeting Anticancer Agents: Rational Approaches, Synthetic Routes and Structure Activity Relationship
Anti-Cancer Agents in Medicinal Chemistry The Role of 3D Pharmacophore Mapping Based Virtual Screening for Identification of Novel Anticancer Agents: An Overview
Current Topics in Medicinal Chemistry The Rb Pathway and Cancer Therapeutics
Current Drug Targets Applications of Aptamers in Targeted Imaging: State of the Art
Current Topics in Medicinal Chemistry Combined Therapies of Bone Disease with Bisphosphonates
Current Pharmaceutical Design Metal-free Reductive Coupling of Biphenyl Tosylhydrazones with Phenols or Benzyl Alcohols
Letters in Organic Chemistry Novel Next-Generation Sequencing and Networks-Based Therapeutic Targets: Realistic and More Effective Drug Design and Discovery
Current Pharmaceutical Design Editorial
Reviews on Recent Clinical Trials Breast Cancer Risks in Premenopausal Women: A Review
Current Women`s Health Reviews Editorial (Thematic Issue: Ubiquitin E3 Ligases as Molecular Targets or Tools for Advanced Cancer Therapy)
Current Cancer Drug Targets PPARδ Signaling Regulates Colorectal Cancer
Current Pharmaceutical Design Mechanistic Studies of Inactivation of Glutathione S-transferase Pi Isozyme by a Haloenol Lactone Derivative
Medicinal Chemistry From ImmunoToxins to ImmunoRNases
Current Pharmaceutical Biotechnology Acetylation Control of Cancer Cell Metabolism
Current Pharmaceutical Design A Combination of Two Antioxidants (An SOD Mimic and Ascorbate) Produces a Pro-Oxidative Effect Forcing Escherichia coli to Adapt Via Induction of oxyR Regulon
Anti-Cancer Agents in Medicinal Chemistry Aromatase: The Enzyme and Its Inhibition
Anti-Cancer Agents in Medicinal Chemistry Nutrition and DNA Repair - Potential Molecular Mechanisms of Action
Current Cancer Drug Targets